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TO THE EDITOR
Psoriasis is an immune-mediated chronic
inflammatory skin disease that affects
approximately 2% of the population. The
etiology of psoriasis is currently un-
known, but the identification of several
psoriasis susceptibility loci suggests that
genetic disposition has an important role
in its development, with environmental
factors acting as triggers.
There are two distinct ages of onset for
psoriasis. Early onset occurs before the
age of 40 years and accounts for 75% of
cases, whereas late onset presents after
the age of 40 years, with a peak between
55 and 60 years of age. Although the two
types of psoriasis appear to be very
similar clinically, they are genetically
distinct. The HLA-Cw6 allele is asso-
ciated with early-onset, but not with late-
onset psoriasis, although this is not
absolute (Henseler and Christophers,
1985; Allen et al., 2005). Indeed, this
allele is found in approximately 43–54%
of early-onset patients, but in only
17–29% of those with late-onset psor-
iasis, the latter being comparable to the
frequency of 14–20% in the general
population (Mallon et al., 1997; Chang
et al., 2003; Allen et al., 2005).
We have found previously that the
function of epidermal Langerhans cells
(LCs), and specifically LC mobilization
and migration, is profoundly impaired in
the uninvolved skin (PN) of early-onset
psoriasis patients compared with the skin
of healthy volunteers (NN). In normal
subjects, skin sensitization (Griffiths
et al., 2001), or the intradermal injection
of either tumor necrosis factor-alpha
(TNF-a) or interleukin-1 beta (IL-1b;
Cumberbatch et al., 1999, 2003), stimu-
lates the mobilization of LCs and their
migration to draining lymph nodes. In
patients with early-onset psoriasis, LC
migration in response to IL-1b, TNF-a,
and a contact allergen was in all cases
shown to be substantially reduced or
completely absent in the PN (Cumber-
batch et al., 2006).
As LC function appears to have a
key role in the pathogenesis of psoriasis
(Cumberbatch et al., 2006; Werner
et al., 2008), we questioned whether
LC migration in response to either TNF-a
or IL-1b is similarly impaired in the PN of
patients with late-onset psoriasis. In all,
10 patients with late-onset psoriasis
(mean age 59.9±1.6; age of onset
54.7±1.1), 5 healthy volunteers (mean
age 64.5±2.2), and 3 patients with
early-onset psoriasis (mean age 57.3±
3.9) provided written informed consent
for the study, which was approved by the
Salford and Trafford Research Ethics
Committee and was conducted in ac-
cordance with the Declaration of
Helsinki. All study participants were
Caucasian. Inclusion criteria included
no use of systemic therapies for 4 weeks
and no use of topical therapies for 2
weeks before participation in the study.
Subjects received one intradermal injec-
tion of saline in the clinically uninvolved
(PN) buttock or hip skin, at a position
Abbreviations: IL-1b, interleukin-1 beta; LC, Langerhans cell; NN, skin of healthy volunteers; PN,
uninvolved skin of patients with psoriasis; TNF-a, tumor necrosis factor-alpha
1940 Journal of Investigative Dermatology (2010), Volume 130
FL Shaw et al.
Langerhans Cell Migration in Psoriasis
45cm from an active plaque of psor-
iasis, and one injection of either IL-1b
(100U) or TNF-a (500U; both from
Insight Biotechnology, Wembley, UK)
in a contralateral, similarly uninvolved
site. This is with the exception of a single
patient with late-onset psoriasis who
received sequentially 50 and 200U of
IL-1b and TNF-a, respectively. Cytokine
concentrations for injection were se-
lected based on dose–response curves
from our previous investigations
(Cumberbatch et al., 1999, 2003). Skin
biopsy specimens (of 6mm diameter)
were taken 2h post-administration from
the injection sites for preparation of
epidermal sheets, and were stained for
CD1a expression for LC enumeration
using fluorescence microscopy as pre-
viously described (Griffiths et al., 2001).
Cytokine-induced changes in LC fre-
quency were compared with previously
published values for NN and PN
from patients with early-onset psoriasis
(Cumberbatch et al., 1999, 2003, 2006).
Data are reported as mean±SEM.
The density of LCs in saline injection
sites of the skin from healthy volunteers
did not differ significantly from
those of patients with late-onset pso-
riasis, being 982.8±60.9 LC/mm2 and
958.4±104.8 LC/mm2, respectively.
Likewise, and as previously reported
(Cumberbatch et al., 2006), there was
no difference in LC frequency in the
PN derived from patients with early-
onset psoriasis compared with the NN
following saline injection (1015.0
±71.5 LC/mm2). These cell counts re-
flect the biological range observed in
humans, as depicted by our historical
data in Figure 1 (closed circles).
Intradermal administration of IL-1b
(100U), as expected, resulted in a
reduction (21.5±5.1%) in the freq-
uency of epidermal LCs in the NN
(Figure 1a (i)). This percentage decrease
is similar to that observed previously
(Figure 1a (i); 19.7±2.0%). The effect of
IL-1b on LC migration in patients with
early-onset psoriasis was also assessed in
one age-matched individual; that is,
upon participation in this study, they
were over 50 years, but their onset of
psoriasis was before the age of 40 years.
Consistent with our previous data, there
was no reduction in epidermal LC
density in this individual (Figure 1a (ii)).
However, in the patients with late-onset
psoriasis, administration of IL-1b resulted
in a significant reduction (26.5±4.4%)
in the frequency of epidermal LCs (Figure
1a (iii); Po0.05).
The intradermal administration of
TNF-a (500U) resulted in a reduction in
epidermal CD1aþ LC frequency of
20.2±0.9% in three healthy volunteers
(Figure 1b (i)). This percentage decrease
is similar to that observed previously, as
depicted by our historical data (Figure 1b
(i); 25.5±1.5%). The effect of TNF-a on
LC migration in two age-matched pa-
tients with early-onset psoriasis was also
measured (Figure 1b (ii)). Consistent with
our previous observations (Figure 1b (ii)),
no LC migration was recorded in these
individuals in response to TNF-a. Inter-
estingly, and in contrast to the effect of IL-
1b, TNF-a administration was also un-
able to stimulate LC migration in patients
with late-onset psoriasis (Figure 1b (iii)).
The impairment of LC migration in
response to TNF-a, but not IL-1b,
injection in patients with late-onset
psoriasis was further verified in one
individual with late-onset psoriasis who
received intradermal injections of both
IL-1b and TNF-a, but on two separate
occasions. As expected, intradermal
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Figure 1. The effect of cytokines on epidermal Langerhans cell frequency in healthy volunteers, and in
patients with early- or late-onset psoriasis. Homologous recombinant (a) interleukin-1 beta (IL-1b;
100U) or (b) tumor necrosis factor-alpha (TNF-a; 500U), and saline as control were injected
intradermally into the skin of (i) healthy volunteers, and into the uninvolved skin of (ii) patients with
early-onset psoriasis and (iii) patients with late-onset psoriasis. Skin biopsies were taken 2 h following
cytokine administration, and epidermal sheets were prepared and assessed for CD1aþ Langerhans cell
(LC) density. Differences in percentage decreases in LC frequency in response to TNF-a and IL-1b
administration in patients with either early- or late-onset psoriasis, and healthy volunteers were analyzed
using two-way analysis of variance. Open circles represent data from the current investigation, and
closed circles represent historical data (Cumberbatch et al., 1999, 2003, 2006). Historical data from our
previous investigations are demonstrated for both (i) healthy volunteers and (ii) patients with early-onset
psoriasis following intradermal injection with either (a) IL-1b (50–100U) or (b) TNF-a (200–500U). Each
line represents the results of one individual.
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a decrease (15.3%) in LC frequency,
whereas there was no change in LC
numbers following administration of
TNF-a (200U; data not shown). Con-
versely, and as expected, both IL-1b
and TNF-a induced LC migration in a
healthy individual (decreases of 11.4
and 21.6%, respectively).
These results reveal a marked differ-
ence in the mobilization of epidermal
LCs in early-onset compared with late-
onset psoriasis. In early-onset psoriasis,
LCs within PN sites respond to neither IL-
1b nor TNF-a, whereas in late-onset
psoriasis, LCs are responsive to IL-1b
but not TNF-a. This failure of exogenous
TNF-a to mobilize LCs does not necessa-
rily reflect unresponsiveness to TNF-a per
se. As LC migration requires the receipt
of signals from both TNF-a and IL-1b,
unresponsiveness in this instance could
be secondary to an impairment of IL-1b
production, bioactivation, and/or signal-
ling. The mechanistic basis for these
important differences in LC migration is
presently unresolved, but is the focus of
current investigations. However, even in
the absence of an appreciation of how
such differential regulation is effected,
the variable mobilization of LCs between
these two forms of psoriasis is striking.
Although not yet exhaustive, these
analyses provide intriguing indications
of important differences in LC function
between early- and late-onset psoriasis.
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TO THE EDITOR
TRPA1 (transient receptor potential
cation channel subfamily A, member 1
(ANKTM1: Ankyrin-like transmem-
brane domains 1)) was first discovered
in nociceptive sensory neurons from
dorsal root ganglia, as one of the
transient receptor potential (TRP) cha-
nnels activated by temperature below
17 oC (Story et al., 2003). Intracellular
calcium elevation and electrical activity
were observed at 17 1C (Story et al.,
2003). TRPA1 is also activated by allyl
isothiocyanate (Jordt et al., 2004) and
cinnamaldehyde (Bandell et al., 2004).
Both reagents induce the elevation of
intracellular calcium and electrical
activity of sensory neurons (Bandell
et al., 2004; Jordt et al., 2004). 2-(1,
3-Dimethyl-2,6-dioxo-1,2,3,6-tetrahydro-
7H-purin-7-yl)-N-(4-isopropylphenyl)ace-
tamide (HC030031) was reported to
be a selective TRPA1 channel blocker
(McNamara et al., 2007). The effect
was examined in human embryonic
kidney 293 cell lines stably expressing
TRPA1, and the IC50 value of HC030031
against allyl isothiocyanate-induced acti-
vation was 6.2mM (McNamara et al.,
2007).
Recently, expression of TRPA1 in
human epidermis was reported (Atoyan
et al., 2009). The involvement of TRP
channels in sensitive skin was sug-
gested (Stander et al., 2009), and
TRPA1 was found to mediate formalin-
induced pain (McNamara et al., 2007).
Abbreviations: HC030031, 2-(1,3-dimethyl-2,6-dioxo-1,2,3,6-tetrahydro-7H-purin-7-yl)-N-(4-
isopropylphenyl)acetamide; TRP, transient receptor potential; TRPA1, transient receptor potential cation
channel subfamily A, member 1
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